Assetmark Inc. Has $1.77 Million Position in Natera, Inc. (NASDAQ:NTRA)

Assetmark Inc. lifted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 51.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,154 shares of the medical research company's stock after buying an additional 3,801 shares during the period. Assetmark Inc.'s holdings in Natera were worth $1,766,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after acquiring an additional 95 shares during the last quarter. Principal Securities Inc. grew its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the period. Finally, True Wealth Design LLC purchased a new stake in Natera in the 3rd quarter worth approximately $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the transaction, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Fesko sold 669 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company's stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 294,946 shares of company stock worth $47,212,702. Insiders own 7.60% of the company's stock.

Remove Ads

Natera Price Performance

Shares of NASDAQ NTRA traded down $1.99 during mid-day trading on Thursday, hitting $142.51. 2,025,383 shares of the stock were exchanged, compared to its average volume of 1,345,255. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The stock's fifty day simple moving average is $164.45 and its two-hundred day simple moving average is $148.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $19.27 billion, a P/E ratio of -80.97 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research report on Tuesday. Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Craig Hallum lifted their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Morgan Stanley increased their price objective on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Barclays started coverage on Natera in a research report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.